Skye Bioscience, Inc.(OTCQB:SKYE)and Emerald Health Therapeutics, Inc. (OTCQB:EMHTF) (CSE:EMH)have entered into a definitive agreementwith respect to a transaction to be completed by way of a plan of arrangementwhereby Skye would acquire all of the issued and outstanding shares of Emeraldin a share-for-share-transaction.
Skye is a San Diego-based pharmaceutical companydeveloping proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet needs. Emerald possesses cash and non-cash assets that Skye would acquire through the arrangement. The proposed arrangement is subject to approval by each...
Login or create a forever free account to read this news
Sign up/Log in